Printer Friendly

Courtagen to Receive US Patent for Genetically Targeted Pain Therapy.

M2 PHARMA-February 24, 2017-Courtagen to Receive US Patent for Genetically Targeted Pain Therapy

(C)2017 M2 COMMUNICATIONS

- US-based endocannabinoid platform and molecular information company Courtagen Life Sciences, Inc. has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application no. 14/895,557, titled "Methods and Kits for Treating and Classifying Individuals at Risk of or Suffering from TRAP1 Change-of-Function," the company said.

Courtagen said the patent application addresses a complementary or companion diagnostic approach for a potential drug target related to a genetic form of chronic pain that may be present in approximately 1% of the population.

The recently published crystal structure of the TRAP1 gene has enabled the company to conduct protein variant predictions, which have highlighted several compounds that fit within the mutated ATPase domain, including notably, cannabidiol from the hemp and cannabis plants.

Courtagen Life Sciences, Inc., located in Woburn, Massachusetts, is a CLIA/CAP certified endocannabinoid platform and molecular information company focused on the diagnosis of a range of neurological, endocrine, and functional disorders associated with the central, peripheral, and autonomic nervous systems, including the endocannabinoid receptor system.

The company operates Next Generation DNA Sequencing, bioinformatics, and clinical interpretation business that helps physicians elucidate the linkages between the genotypes and phenotypes of various diseases, which may be treated with a host of therapies, including pharmaceutical drugs and medical cannabis.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 24, 2017
Words:242
Previous Article:Cynvenio and Color Partner to Offer Comprehensive Hereditary and Somatic Cancer Testing.
Next Article:Incyte Forms Oncology Research Alliance with the University of Pennsylvania's Abramson Cancer Center.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters